Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Increased risk for invasive breast cancer associated with hormonal therapy: a nation-wide random sample of 65,723 women followed from 1997 to 2008.

Lai JN, Wu CT, Chen PC, Huang CS, Chow SN, Wang JD.

PLoS One. 2011;6(10):e25183. doi: 10.1371/journal.pone.0025183. Epub 2011 Oct 6.

2.

Hormone therapy and breast cancer: what factors modify the association?

Gertig DM, Fletcher AS, English DR, Macinnis RJ, Hopper JL, Giles GG.

Menopause. 2006 Mar-Apr;13(2):178-84.

PMID:
16645531
3.

Influence of estrogen plus testosterone supplementation on breast cancer.

Ness RB, Albano JD, McTiernan A, Cauley JA.

Arch Intern Med. 2009 Jan 12;169(1):41-6. doi: 10.1001/archinternmed.2008.507.

PMID:
19139322
4.

Breast cancer among young U.S. women in relation to oral contraceptive use.

White E, Malone KE, Weiss NS, Daling JR.

J Natl Cancer Inst. 1994 Apr 6;86(7):505-14.

PMID:
8133534
5.

A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: the women's health in the Lund area (WHILA) study (Sweden).

Jernström H, Bendahl PO, Lidfeldt J, Nerbrand C, Agardh CD, Samsioe G.

Cancer Causes Control. 2003 Sep;14(7):673-80.

PMID:
14575365
6.

Concurrent Use in Taiwan of Chinese Herbal Medicine Therapies among Hormone Users Aged 55 Years to 79 Years and Its Association with Breast Cancer Risk: A Population-Based Study.

Tsai YT, Lai JN, Wu CT, Lin SK.

Evid Based Complement Alternat Med. 2014;2014:683570. doi: 10.1155/2014/683570. Epub 2014 May 29.

7.

Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study.

Tjønneland A, Christensen J, Thomsen BL, Olsen A, Overvad K, Ewertz M, Mellemkjaer L.

Cancer. 2004 Jun 1;100(11):2328-37.

8.

Alcohol consumption and risk of postmenopausal breast cancer by subtype: the women's health initiative observational study.

Li CI, Chlebowski RT, Freiberg M, Johnson KC, Kuller L, Lane D, Lessin L, O'Sullivan MJ, Wactawski-Wende J, Yasmeen S, Prentice R.

J Natl Cancer Inst. 2010 Sep 22;102(18):1422-31. doi: 10.1093/jnci/djq316. Epub 2010 Aug 23.

9.

[Hormone replacement therapy in menopause and risk of breast cancer].

Clavel-Chapelon F, Hill C.

Presse Med. 2000 Oct 21;29(31):1688-93. Review. French.

PMID:
11094609
10.

Breast cancer risk with postmenopausal hormonal treatment.

Collins JA, Blake JM, Crosignani PG.

Hum Reprod Update. 2005 Nov-Dec;11(6):545-60. Epub 2005 Sep 8. Review. Erratum in: Hum Reprod Update. 2006 May-Jun;12(3):331.

11.
12.
13.

Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement.

Persson I, Weiderpass E, Bergkvist L, Bergström R, Schairer C.

Cancer Causes Control. 1999 Aug;10(4):253-60.

PMID:
10482483
14.

Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.

Anderson GL, Chlebowski RT, Rossouw JE, Rodabough RJ, McTiernan A, Margolis KL, Aggerwal A, David Curb J, Hendrix SL, Allan Hubbell F, Khandekar J, Lane DS, Lasser N, Lopez AM, Potter J, Ritenbaugh C.

Maturitas. 2006 Sep 20;55(2):103-15. Epub 2006 Jul 11.

PMID:
16815651
15.

The use of Chinese herbal products and its influence on tamoxifen induced endometrial cancer risk among female breast cancer patients: a population-based study.

Tsai YT, Lai JN, Wu CT.

J Ethnopharmacol. 2014 Sep 11;155(2):1256-62. doi: 10.1016/j.jep.2014.07.008. Epub 2014 Jul 15.

PMID:
25048609
16.

Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography.

Laya MB, Larson EB, Taplin SH, White E.

J Natl Cancer Inst. 1996 May 15;88(10):643-9.

17.

Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy.

Stahlberg C, Pedersen AT, Andersen ZJ, Keiding N, Hundrup YA, Obel EB, Møller S, Rank F, Ottesen B, Lynge E.

Br J Cancer. 2004 Aug 16;91(4):644-50.

18.

Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.

Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA.

Cancer. 2004 Oct 1;101(7):1490-500.

19.

Dietary acrylamide intake and estrogen and progesterone receptor-defined postmenopausal breast cancer risk.

Pedersen GS, Hogervorst JG, Schouten LJ, Konings EJ, Goldbohm RA, van den Brandt PA.

Breast Cancer Res Treat. 2010 Jul;122(1):199-210. doi: 10.1007/s10549-009-0642-4. Epub 2009 Dec 1.

PMID:
19949857
20.

Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.

Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, Kim-Sing C, Neuhausen SL, Gilbert L, Ghadirian P, Manoukian S, Rennert G, Friedman E, Isaacs C, Rosen E, Rosen B, Daly M, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.

J Natl Cancer Inst. 2008 Oct 1;100(19):1361-7. doi: 10.1093/jnci/djn313. Epub 2008 Sep 23.

Items per page

Supplemental Content

Write to the Help Desk